セフタジジム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P272：汚染された作業衣は作業場から出さないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P284：呼吸用保護具を着用すること。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P333+P313：皮膚刺激または発疹が生じた場合：医師の診断/手当てを 受けること。

セフタジジム 価格

セフタジジム 化学特性,用途語,生産方法

• 効能

  抗生物質, 細胞壁合成阻害薬

• 商品名

  モダシン (グラクソ・スミスクライン)

• 説明

  Ceftazidime is the latest third generation cephalosporin to reach the market. It has one of the broadest spectrums of the cephalosporins, similar in many regards to that of cefotaxime. It is particularly active against Pseudomonas aeruginosa, being perhaps 4-5 times more potent in vitro than moxalactam and cefotaxime.

• 化学的特性

  White Solid

• 使用

  Ceftazidime pentahydrate is an antibacterial agent. It is used especially for Pseudomonas and other gram-negative infections in debilitated patients. It is used in the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).

• 定義

  ChEBI: A hydrate that is the pentahydrate of ceftazidime, a cephalosporin having 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino and 3-pyridinium-1-ylmethyl side-groups.

• 抗菌性

  Its activity is comparable to that of cefotaxime and ceftizoxime, but it is more active against Ps. aeruginosa, including almost all gentamicin-resistant strains, and Burk. cepacia. It is, however, less active against Staph. aureus. It is stable to a wide range of β-lactamases, but is hydrolyzed by some TEM variants.

• 臨床応用

  It is used, often combined with an aminoglycoside, to treat a wide range of severe urinary, respiratory and wound infections, mostly due to enterobacteria or Ps. aeruginosa. Reference is made to its use in pneumonia, septicemia, meningitis (especially if caused by Ps. aeruginosa), peritonitis, osteomyelitis, neonatal sepsis, burns and melioidosis. Concern has been expressed at the relative frequency with which failure is associated with superinfection or the emergence of resistance.

• 副作用

  It is generally well tolerated. Preparations containing arginine have replaced those with sodium carbonate, which causes pain on intramuscular injection. Reactions common to cephalosporins have been observed in some patients, including positive antiglobulin tests without hemolysis, raised liver function test values, eosinophilia, rashes, leukopenia, thrombocytopenia and diarrhea, occasionally associated with toxigenic C. difficile.
  Failure of therapy has been associated with superinfection with resistant organisms, including Staph. aureus, enterococci and Candida. Resistance caused by induction of chromosomal β-lactamases may emerge in Ps. aeruginosa, Ser. marcescens or Enterobacter spp.

セフタジジム 上流と下流の製品情報

セフタジジム 生産企業

Global(266)Suppliers

セフタジジム スペクトルデータ(¹HNMR)

78439-06-2, セフタジジム キーワード